All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma

URN to cite this document:: urn:nbn:de:bvb:355-epub-543205
DOI to cite this document:: 10.5283/epub.54320

Fante, Matthias A. ; Harrer, Dennis C.

; Zartner, Barbara ; Lüke, Florian

; Mayer, Stephanie ; Menhart, Karin

; Reichle, Albrecht

; Herr, Wolfgang ; Vogelhuber, Martin ; Heudobler, Daniel

License: Creative Commons Attribution 4.0
PDF - Published Version
(3MB)

Date of publication of this fulltext: 06 Jun 2023 05:38

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Purpose: Peripheral T-cell lymphoma (PTCL) is a rare and heterogenous hematologic malignancy with poor prognosis especially in elderly and frail patients who are not eligible for intensive treatment. The resulting palliative setting necessitates tolerable but effective schedules for outpatient treatment. TEPIP is a locally developed, all-oral low-dose regimen comprising trofosfamide, etoposide, ...